Vanguard Global Advisers
XLO icon

Vanguard Global Advisers’s Xilio Therapeutics XLO Stock Holding History

Vanguard Global Advisers’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-210
Closed -$1.77K – 3746
2026
Q1 		$1.77K Buy
+210
New +$1.72K ﹤0.01% 3622

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's XLO Position: Q2 2026 in Review

Vanguard Global Advisers sold out of Xilio Therapeutics (XLO) in Q2 2026, closing a stake of 210 shares — an estimated $1.77K sold.

Vanguard Global Advisers first reported a position in XLO in Q1 2026 and held it in 1 quarter. The position peaked at $1.77K in Q1 2026. 24 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • Vanguard Global Advisers reported no remaining Xilio Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 210 Xilio Therapeutics shares in Q2 2026, an estimated $1.77K.
  • Vanguard Global Advisers first reported a position in Xilio Therapeutics in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's Xilio Therapeutics position peaked at $1.77K in Q1 2026.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.